Marinus Pharmaceuticals downgraded by Oppenheimer with a new price target
$MRNS
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer downgraded Marinus Pharmaceuticals from Outperform to Perform and set a new price target of $9.00 from $14.00 previously